The silent and dangerous inequity around access to COVID-19 testing: A call to action

Carolina Batista; Peter Hotez; Yanis Ben Amor; Jerome H. Kim; David Kaslow; Bhavna Lall; Onder Ergonul; J. Peter Figueroa; Mayda Gursel; Mazen Hassanain; Gagandeep Kang; Heidi Larson; Denise Naniche; Timothy Sheahan; Annelies Wilder-Smith; Shmuel Shoham; Samba O. Sow; Prashant Yadav; Nathalie Strub-Wourgaft; Sarah Jane Loveday; Emma Hannay; Maria Elena Bottazzi

doi:10.1016/j.eclinm.2021.101230

The silent and dangerous inequity around access to COVID-19 testing: A call to action

Carolina Batista, Peter Hotez, Yanis Ben Amor, Jerome H. Kim, David Kaslow, Bhavna Lall, Onder Ergonul, J. Peter Figueroa, Mayda Gursel, Mazen Hassanain, Gagandeep Kang, Heidi Larson, Denise Naniche, Timothy Sheahan, Annelies Wilder-Smith, Shmuel Shoham, Samba O. Sow, Prashant Yadav, Nathalie Strub-Wourgaft, Sarah Jane LovedayEmma Hannay, Maria Elena Bottazzi

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Article number	101230
Journal	EClinicalMedicine
Volume	43
DOIs	https://doi.org/10.1016/j.eclinm.2021.101230
State	Published - Jan 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.eclinm.2021.101230

Cite this

Batista, C., Hotez, P., Amor, Y. B., Kim, J. H., Kaslow, D., Lall, B., Ergonul, O., Figueroa, J. P., Gursel, M., Hassanain, M., Kang, G., Larson, H., Naniche, D., Sheahan, T., Wilder-Smith, A., Shoham, S., Sow, S. O., Yadav, P., Strub-Wourgaft, N., ... Bottazzi, M. E. (2022). The silent and dangerous inequity around access to COVID-19 testing: A call to action. EClinicalMedicine, 43, Article 101230. https://doi.org/10.1016/j.eclinm.2021.101230

Batista, C, Hotez, P, Amor, YB, Kim, JH, Kaslow, D, Lall, B, Ergonul, O, Figueroa, JP, Gursel, M, Hassanain, M, Kang, G, Larson, H, Naniche, D, Sheahan, T, Wilder-Smith, A, Shoham, S, Sow, SO, Yadav, P, Strub-Wourgaft, N, Loveday, SJ, Hannay, E & Bottazzi, ME 2022, 'The silent and dangerous inequity around access to COVID-19 testing: A call to action', EClinicalMedicine, vol. 43, 101230. https://doi.org/10.1016/j.eclinm.2021.101230

@article{85fd631c13df4d9096326f183a640f6e,

title = "The silent and dangerous inequity around access to COVID-19 testing: A call to action",

author = "Carolina Batista and Peter Hotez and Amor, {Yanis Ben} and Kim, {Jerome H.} and David Kaslow and Bhavna Lall and Onder Ergonul and Figueroa, {J. Peter} and Mayda Gursel and Mazen Hassanain and Gagandeep Kang and Heidi Larson and Denise Naniche and Timothy Sheahan and Annelies Wilder-Smith and Shmuel Shoham and Sow, {Samba O.} and Prashant Yadav and Nathalie Strub-Wourgaft and Loveday, {Sarah Jane} and Emma Hannay and Bottazzi, {Maria Elena}",

note = "Funding Information: MEB and PJH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (T{\"U}BİTAK) since March 2020. MH is Founder and Managing Director of SaudiVax. JPF, GK and DCK are members of the WHO SAGE Working Group on COVID-19 vaccines. GK is independent director appointed by the Wellcome Trust, MSD Wellcome Trust Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). DCK reports grants from Bill and Melinda Gates Foundation (BMGF) and grants from CEPI, JHK reports personal fees from SK biosciences. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, grants from J&J outside the submitted work. AWS serves as Consultant to WHO. The views presented here reflect her views and not necessarily those of WHO. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline, and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, Celltrion, and Adagio outside the submitted work. EH and S-JL are currently employed by FIND. All the other authors report no conflicts. ",

year = "2022",

month = jan,

doi = "10.1016/j.eclinm.2021.101230",

language = "English (US)",

volume = "43",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - The silent and dangerous inequity around access to COVID-19 testing

T2 - A call to action

AU - Batista, Carolina

AU - Hotez, Peter

AU - Amor, Yanis Ben

AU - Kim, Jerome H.

AU - Kaslow, David

AU - Lall, Bhavna

AU - Ergonul, Onder

AU - Figueroa, J. Peter

AU - Gursel, Mayda

AU - Hassanain, Mazen

AU - Kang, Gagandeep

AU - Larson, Heidi

AU - Naniche, Denise

AU - Sheahan, Timothy

AU - Wilder-Smith, Annelies

AU - Shoham, Shmuel

AU - Sow, Samba O.

AU - Yadav, Prashant

AU - Strub-Wourgaft, Nathalie

AU - Loveday, Sarah Jane

AU - Hannay, Emma

AU - Bottazzi, Maria Elena

N1 - Funding Information: MEB and PJH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK) since March 2020. MH is Founder and Managing Director of SaudiVax. JPF, GK and DCK are members of the WHO SAGE Working Group on COVID-19 vaccines. GK is independent director appointed by the Wellcome Trust, MSD Wellcome Trust Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). DCK reports grants from Bill and Melinda Gates Foundation (BMGF) and grants from CEPI, JHK reports personal fees from SK biosciences. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, grants from J&J outside the submitted work. AWS serves as Consultant to WHO. The views presented here reflect her views and not necessarily those of WHO. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline, and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, Celltrion, and Adagio outside the submitted work. EH and S-JL are currently employed by FIND. All the other authors report no conflicts.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85121137536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121137536&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2021.101230

DO - 10.1016/j.eclinm.2021.101230

M3 - Comment/debate

C2 - 34927038

AN - SCOPUS:85121137536

SN - 2589-5370

VL - 43

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 101230

ER -

The silent and dangerous inequity around access to COVID-19 testing: A call to action

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this